Wikisage, the free encyclopedia of the second generation, is digital heritage

Difference between revisions of "Belzutifan"

From Wikisage
Jump to navigation Jump to search
(ATC)
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.
+
Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von [[Hippel-Lindau disease]].
  
 
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
 
Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).
Line 14: Line 14:
 
[[File:Buecher_Regal_636.jpg|32px]]
 
[[File:Buecher_Regal_636.jpg|32px]]
 
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref>
 
Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs<ref>Dictionary of Medical eponyms</ref>
 +
 +
==External links==
 +
[https://www.karger.com/Article/FullText/431323 Ben-Skowronek I, Kozaczuk S] 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323
  
 
{{wikidata|Q27456641}}
 
{{wikidata|Q27456641}}
 +
 +
 +
{{refs}}
 +
 +
[[nl:Belzutifan]]

Latest revision as of 00:05, 14 August 2021

Belzutifan is a drug being approved for the treatment of renal cell carcinoma associated with von Hippel-Lindau disease.

Belzutifan is an inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α).

Belzutifan is the first drug to be awarded an "innovation passport" by the UK Medicines and Healthcare products Regulatory Agency (MHRA)[1]

ATC

none

Belzutifan.png
belzutifan

Buecher Regal 636.jpg Retinal angioma associated with cerebellar angioma and sometimes angioma in other organs[2]

External links

Ben-Skowronek I, Kozaczuk S 2015: Von Hippel-Lindau Syndrome. Horm Res Paediatr 84:145-152. doi: 10.1159/000431323

Q27456641 op Wikidata  Interwiki via Wikidata


References

References: